Table 2 Pooled vaccine efficacy/effectiveness (VE) of PPV-23 against IPD and pneumococcal pneumonia (data from [83]).
From: Vaccination of older adults: Influenza, pneumococcal disease, herpes zoster, COVID-19 and beyond
| Â | clinical trials VE [%] (95%CI) | cohort studies | case-control studies |
|---|---|---|---|
IPD | 73% (10-92) | 45% (15-65) | 59% (35-74) |
pneumococcal pneumonia | 64% (32-80) | 48% (25-63) | n.d. |